Meet the 2023 AP and GL Trustee candidates

Anatomy and Pathology/Oncology (AP) Trustee candidate

Matthew Wilson, MD, FACS It is a pleasure to endorse the nomination of Matthew W. Wilson, MD, FACS for ARVO Anatomy and Pathology/Oncology (AP) Trustee. Dr Wilson has worked in the field of eye research since early 1990’s and has been an active participant ARVO member since 1994. I am an ARVO (AP) regular member since 1991 and have worked with Dr. Wilson outside and inside ARVO committees and meetings for more than 20 years. I know Matt has the drive, commitment, leadership skills and the knowledge of ARVO’s goals and values needed for effectively representing and serving as AP Trustee.  

Endorsed by:

Patricia Chévez-Barrios, MD
Houston Methodist Hospital

Glaucoma (GL) Trustee candidates

C. Ross Ethier, PhD, FARVO I strongly endorse the nomination of C. Ross Ethier for GL Section Trustee. Since 2004, I have been impressed with how he applies his engineering background to problems in both the front and back of the eye. Although a non-clinician, his solid understanding of clinical glaucoma gives his work a practical value that will lead to real therapeutic solutions. He is an excellent scientist, an experienced, collegial and reliable leader, and an excellent listener. He will be an outstanding ARVO Trustee who will effectively advocate for all of glaucoma research

Endorsed by:

John C. Morrison, MD
Fred P and Joan Thompson Family Professor of Ophthalmology 
Casey Eye Institute


Joel Schuman, MD, FARVO It is my distinct pleasure to nominate Joel S. Schuman, MD for ARVO Trustee.

Dr. Schuman has outstanding accomplishments in Ophthalmology:

(a) He is an inventor of optical coherence tomography (OCT), a technology that advances the progress of ophthalmology in all parts of the world.
(b) He has conducted and published outstanding original investigations in ophthalmology.
(c) He has made significant contributions as an ophthalmic educator.
(d) He has demonstrated meritorious and remarkable service to ophthalmology and to ARVO.

Dr. Schuman is an internationally recognized innovator advancing vision research and modern eye care. Dr. Schuman and colleagues invented optical coherence tomography, a non-invasive high resolution in vivo imaging device used ubiquitously worldwide for the diagnosis and management of eye and related conditions, revolutionizing our understanding of disease processes, transforming care, and reducing the risk of blindness in millions of people globally. His major, long-standing research contributions have been focused on the development, evolution, and utility of Optical Coherence Tomography (OCT) for imaging the eye, with >150 OCT related peer reviewed scientific papers in high-impact journals, including Science and Nature Medicine.  OCT has revolutionized ophthalmology and is now the gold standard, clinical tool for diagnosing, treating and monitoring the most important blinding diseases of the industrialized world: macular degeneration, diabetic retinopathy and glaucoma. OCT allows non-invasive in vivo objective, finely quantitative assessment of ocular pathologies.

In addition, Dr. Schuman and colleagues reported in Nature Medicine the identification of the first molecular marker for glaucoma. Many other investigators have built broadly on this seminal work.

Dr. Schuman has been recognized with numerous awards and has held multiple leadership positions. Dr. Schuman’s works have been cited 65,294 times; his h-index is 103.

I nominate Joel S. Schuman, MD without reservation and with the greatest possible enthusiasm for ARVO Trustee.

Nominated by:

Janey L. Wiggs, MD, PhD
Paul Austin Chandler Professor of Ophthalmology Harvard Medical School
Co-Director, Glaucoma Center of Excellence Vice Chair, Clinical Research
Associate Director, Ocular Genomics Institute Mass. Eye and Ear
Associate Director, Howe Laboratory
Associate Chief, Ophthalmology Clinical Research Senior Scientist